[go: up one dir, main page]

MX2023005658A - Formulaciones de gel, ungüento y espuma de tapinarof y metodos de uso. - Google Patents

Formulaciones de gel, ungüento y espuma de tapinarof y metodos de uso.

Info

Publication number
MX2023005658A
MX2023005658A MX2023005658A MX2023005658A MX2023005658A MX 2023005658 A MX2023005658 A MX 2023005658A MX 2023005658 A MX2023005658 A MX 2023005658A MX 2023005658 A MX2023005658 A MX 2023005658A MX 2023005658 A MX2023005658 A MX 2023005658A
Authority
MX
Mexico
Prior art keywords
gel
tapinarof
ointment
methods
foam formulations
Prior art date
Application number
MX2023005658A
Other languages
English (en)
Inventor
Haripriya Kalluri
Reinilda Catubig
Biljana Roughan
Richard Buchta
Bonjour Florencia Maria Guidali
Brendan Philip Brady
Laura Helen Sutcliffe
Piyush Jain
Glenn Tabolt
David Scott Rubenstein
Original Assignee
Dermavant Sciences GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dermavant Sciences GmbH filed Critical Dermavant Sciences GmbH
Publication of MX2023005658A publication Critical patent/MX2023005658A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Las modalidades descritas en la presente se refieren a composiciones farmacéuticas tópicas que comprenden tapinarof, en donde la composición farmacéutica tópica se formula como un gel acuoso, un gel anhidro, un ungúento o una espuma. Las modalidades también se refieren a 1nétodos para tratar una condición o trastorno dermatológico en un paciente al administrar las presentes composiciones a la piel del paciente.
MX2023005658A 2020-11-23 2021-11-23 Formulaciones de gel, ungüento y espuma de tapinarof y metodos de uso. MX2023005658A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063117235P 2020-11-23 2020-11-23
PCT/US2021/072574 WO2022109626A1 (en) 2020-11-23 2021-11-23 Gel, ointment, and foam formulations of tapinarof and methods of use

Publications (1)

Publication Number Publication Date
MX2023005658A true MX2023005658A (es) 2023-09-07

Family

ID=81658804

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005658A MX2023005658A (es) 2020-11-23 2021-11-23 Formulaciones de gel, ungüento y espuma de tapinarof y metodos de uso.

Country Status (10)

Country Link
US (1) US20220160650A1 (es)
EP (1) EP4247349A4 (es)
JP (1) JP2023550085A (es)
KR (1) KR20230122024A (es)
CN (1) CN116723864A (es)
AU (1) AU2021382046A1 (es)
CA (1) CA3198952A1 (es)
IL (1) IL303008A (es)
MX (1) MX2023005658A (es)
WO (1) WO2022109626A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116983312B (zh) * 2023-05-24 2024-07-05 凌科药业(杭州)有限公司 一种药物组合物、外用制剂及其制备方法、应用
WO2025055906A1 (zh) * 2023-09-12 2025-03-20 广州嘉越医药科技有限公司 吡咯并嘧啶类化合物的用途及其组合物
WO2025092809A1 (zh) * 2023-11-02 2025-05-08 上海泽德曼医药科技有限公司 稳定性改善的苯酚衍生物的药物组合物及其用途
WO2025147725A1 (en) * 2024-01-07 2025-07-10 Cage Bio, Inc. Topical compositions containing tofacitinib and ionic liquid

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8486374B2 (en) * 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
MXPA06003316A (es) * 2003-10-10 2006-06-08 Antares Pharma Ipl Ag Formulacion farmaceutica transdermica para minimizar los residuos en la piel.
AU2010278915A1 (en) * 2009-07-30 2012-03-01 Allergan, Inc. Combination of dapsone with adapalene
CN102579322B (zh) * 2012-03-29 2013-10-23 河北科技大学 一种外用水凝胶剂及其制备方法与它的用途
JP6285946B2 (ja) * 2012-11-20 2018-02-28 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 局所用ダプソンおよびダプソン／アダパレン組成物、ならびにその使用方法
DK3297605T3 (da) * 2015-05-21 2022-06-07 Dermavant Sciences GmbH Topiske, farmaceutiske sammesætninger
US11617724B2 (en) * 2015-05-21 2023-04-04 Dermavant Sciences GmbH Topical pharmaceutical compositions
AU2018365241B2 (en) * 2017-11-10 2023-09-14 Dermavant Sciences GmbH Process for preparing tapinarof
US11497718B2 (en) * 2018-11-13 2022-11-15 Dermavant Sciences GmbH Use of tapinarof for the treatment of atopic dermatitis
US20200147000A1 (en) * 2018-11-13 2020-05-14 Dermavant Sciences GmbH Use of tapinarof for the treatment of chronic plaque psoriasis
EP3902524A4 (en) * 2018-12-25 2022-09-14 Sol-Gel Technologies Ltd. TREATMENT OF SKIN DISORDERS WITH COMPOSITIONS COMPRISING AN EGFR INHIBITOR
CA3127856A1 (en) * 2019-01-27 2020-07-30 Sol-Gel Technologies Ltd. Treatment of skin disorders with topical tapinarof combination compositions
US20220202737A1 (en) * 2019-03-26 2022-06-30 Sol-Gel Technologies Ltd. Treatment of hidradenitis suppurativa with tapinarof compositions
KR20220022115A (ko) * 2019-04-17 2022-02-24 아조라 테라퓨틱스 인코포레이티드 염증성 피부 질환을 치료하기 위한 국소 조성물 및 방법
US20210346279A1 (en) * 2020-05-07 2021-11-11 Sol-Gel Technologies Ltd. Compositions comprising tapinarof for the treatment of pruritis

Also Published As

Publication number Publication date
JP2023550085A (ja) 2023-11-30
CA3198952A1 (en) 2022-05-27
WO2022109626A1 (en) 2022-05-27
KR20230122024A (ko) 2023-08-22
US20220160650A1 (en) 2022-05-26
AU2021382046A1 (en) 2023-06-22
CN116723864A (zh) 2023-09-08
EP4247349A1 (en) 2023-09-27
EP4247349A4 (en) 2025-01-08
IL303008A (en) 2023-07-01

Similar Documents

Publication Publication Date Title
MX2023005658A (es) Formulaciones de gel, ungüento y espuma de tapinarof y metodos de uso.
BR112015005339A8 (pt) uso de óleo de semente de fruta milagrosa como um ingrediente ativo
BRPI0925036B8 (pt) uso de trans-t-butil ciclo-hexanol, composição cosmética, medicamento, seus usos e processos para tratar irritação na pele
RU2012149863A (ru) Полисахарид семени тамаринда для применения в лечении микробных инфекций
CA2396186A1 (en) Agents for the treatment of skin disorders
BRPI0817804A8 (pt) Agente terapêutico para melhorar as propriedades da pele compreendendo um derivado de morfinano ou qualquer um de seus sais de adição de ácido farmacologicamente permissíveis como um ingrediente ativo
EA201071043A1 (ru) Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1 и cx3cr1
UA93995C2 (ru) Фармацевтическая композиция для лечения ожогов (варианты) и способ ee получения
PH12019502874A1 (en) Antibacterial activity of galactooligosaccharide and xylitol in dermatological treatments
ATE413181T1 (de) Therapeutische topische hautlösung und relevante anwendungsmethoden
RU2012149868A (ru) Полисахарид семян для применения в лечении воспалительных заболеваний
MX2023001789A (es) Composiciones naturales para el cuidado de la piel.
MX382949B (es) Formulaciones tópicas de detomidina.
BRPI0417116A (pt) usos de uma quantidade eficaz de ondansetron e composição para tratamento tópico de uma inflamação
EA202092077A1 (ru) Местные составы, содержащие стронций и метилсульфонилметан (мсм), и способы лечения
WO2025185523A8 (zh) 环肽及其组合物和用途
DK2004235T3 (da) Sammensætning til kosmetisk eller farmaceutisk-dermatologisk anvendelse
ES2971823T3 (es) Mejora de las acciones antibacterianas de un antibiótico depsipeptídico mediante cantidades sinérgicas de ácido bórico
TR201619953A2 (tr) Topi̇kal terapöti̇k formülasyonlar
BR112023023213A2 (pt) Métodos para reduzir e para tratar o aparecimento de cicatrizes atróficas de acne ou cicatrizes atróficas pós-acne, e, composto
EP3348307B1 (en) Composition comprising carnitine, sodium cholate, sodium acetate and optionally silver for use in the treatment of psoriasis
MX2013010936A (es) Uso del mucilago de nopal opuntia ficus-indica en combinacion con agentes humectantes convencionales como ingredientes activos en composiciones cosmeticas y/o demartologicas.
MX2020013751A (es) Composicion dermatologica para uso topico en polvo efervescente.
TR202106097A2 (tr) Tenoksi̇kam i̇çeren geli̇şti̇ri̇lmi̇ş jel formülasyonlari
CO2025005816A2 (es) Composiciones tópicas que comprenden un componente de estetrol y uso de dichas composiciones para la cicatrización de heridas